Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric case‐control study

To determine whether Chlamydia trachomatis infection is consistently associated with an increased risk of invasive cervical carcinoma (ICC) after accounting for the strong effect of human papillomavirus (HPV) infection, a case‐control study of 1,238 cases of ICC and 1,100 control women from 7 countries was carried out (hospital‐based studies in Thailand, the Philippines, Morocco, Peru, Brazil and population‐based studies in Colombia and Spain, all coordinated by the International Agency for Research on Cancer, Lyon, France). C. trachomatis serum antibody detection was made by means of a microfluorescence assay. Among HPV DNA‐positive cases and controls, the risk of squamous cell ICC was elevated in C. trachomatis seropositive women (OR = 1.8; 95% CI = 1.2–2.7) after adjustment for age, center, oral contraceptive use, history of Pap smears, number of full‐term pregnancies and herpes simplex virus 2 seropositivity. The effect of C. trachomatis seropositivity on squamous cell ICC risk increased with increasing C. trachomatis antibody titers and was higher in women under 55 years of age. C. trachomatis antibodies were not associated with adeno‐ or adenosquamous cell carcinoma (OR = 1.0; 95% CI = 0.53–1.9) in HPV DNA‐positive women. An association of C. trachomatis with squamous cell ICC was found among all cases and control women with or without adjustment for HPV. © 2004 Wiley‐Liss, Inc.

[1]  R. Peto,et al.  Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study , 1996, BMJ.

[2]  F. X. Bosch,et al.  Causes of cervical cancer in the Philippines: a case-control study. , 1998, Journal of the National Cancer Institute.

[3]  V. Moreno,et al.  Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study , 2002, The Lancet.

[4]  P. Saikku,et al.  Persistence of chlamydial antibodies after pelvic inflammatory disease , 1986, Journal of clinical microbiology.

[5]  P. Bossuyt,et al.  Chlamydia antibody titres: letter , 1999 .

[6]  R. Stone.  Harrison's Principles of Internal Medicine , 1991 .

[7]  M. Sherman,et al.  An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  E. Felley-Bosco.  Role of nitric oxide in genotoxicity: Implication for carcinogenesis , 1998, Cancer and Metastasis Reviews.

[9]  J. Kaldor,et al.  The causal link between human papillomavirus and invasive cervical cancer: A population‐based case‐control study in colombia and spain , 1992, International journal of cancer.

[10]  R. Ashley.  Type specific antibodies to HSV-1 and -2 , 1998 .

[11]  V. Beral,et al.  Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk , 1993, The Lancet.

[12]  P. Saikku,et al.  Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. , 2001, JAMA.

[13]  F. Wiklund,et al.  A population-based seroepidemiological study of cervical cancer. , 1994, Cancer research.

[14]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[15]  P. Castle,et al.  Chlamydia trachomatis and cervical squamous cell carcinoma. , 2001, JAMA.

[16]  J. Land,et al.  How to use Chlamydia antibody testing in subfertility patients. , 1998, Human reproduction.

[17]  P. Bossuyt,et al.  Chlamydia antibody titres. , 1999, Human reproduction.

[18]  Y. Ngeow.  Limitations of serodiagnosis in chlamydial genital tract infections. , 1996, Annals of the Academy of Medicine, Singapore.

[19]  F. X. Bosch,et al.  Risk factors for cervical cancer in Thailand: a case-control study. , 1998, Journal of the National Cancer Institute.

[20]  F. Wiklund,et al.  A population‐based prospective study of Chlamydia trachomatis infection and cervical carcinoma , 2002, International journal of cancer.

[21]  R. Peeling,et al.  Chlamydia trachomatis antigens: role in immunity and pathogenesis. , 1994, Infectious agents and disease.

[22]  F. X. Bosch,et al.  Sexually transmitted agents and cervical neoplasia in colombia and Spain , 1994, International journal of cancer.

[23]  D. Nance,et al.  Inhibition of Apoptosis in Chlamydia-infected Cells: Blockade of Mitochondrial Cytochrome c Release and Caspase Activation , 1998, The Journal of experimental medicine.

[24]  H. Pfister,et al.  State of the art regarding evidence of the viral origin of cervical cancer. , 1991, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[25]  A. Moscicki,et al.  The significance of squamous metaplasia in the development of low grade squamous intraepithelial lesions in young women , 1999, Cancer.

[26]  M. Fay,et al.  Chlamydia trachomatis Disrupts N-Cadherin-Dependent Cell-Cell Junctions and Sequesters β-Catenin in Human Cervical Epithelial Cells , 2002, Infection and Immunity.

[27]  V. Moreno,et al.  Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study , 2002, The Lancet.

[28]  D. Coonrod.  Chlamydial infections. , 2002, Current women's health reports.

[29]  N. Breslow,et al.  Statistical methods in cancer research: volume 1- The analysis of case-control studies , 1980 .

[30]  F. X. Bosch,et al.  Human papillomavirus and invasive cervical cancer in Brazil. , 1994, British Journal of Cancer.

[31]  N. Muñoz,et al.  The viral origin of cervical cancer in Rabat, Morocco , 1998, International journal of cancer.

[32]  N. Muñoz,et al.  HPV types and cofactors causing cervical cancer in Peru , 2001, British Journal of Cancer.

[33]  T. Bjørge,et al.  Chlamydia trachomatis infection as a risk factor for invasive cervical cancer , 2000, International journal of cancer.

[34]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[35]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[36]  J. Bigby.  Harrison's Principles of Internal Medicine , 1988 .

[37]  K. Holmes,et al.  Cytologic manifestations of cervical and vaginal infections. I. Epithelial and inflammatory cellular changes. , 1985, JAMA.

[38]  R. Peeling,et al.  Antibody to chlamydial hsp60 predicts an increased risk for chlamydial pelvic inflammatory disease. , 1997, The Journal of infectious diseases.

[39]  R. Peeling,et al.  Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. , 2002, The Journal of infectious diseases.

[40]  N. Breslow,et al.  Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. , 1981 .

[41]  T. Powles.  Breast cancer prevention , 1999, Breast Cancer Research.

[42]  R. Peeling,et al.  Prevalence and correlates of antibody to chlamydial heat shock protein in women attending sexually transmitted disease clinics and women with confirmed pelvic inflammatory disease. , 1997, The Journal of infectious diseases.

[43]  Ngeow Yf.  Limitations of serodiagnosis in chlamydial genital tract infections. , 1996 .

[44]  N. Muñoz,et al.  Prevalence and Risk Factors for Herpes Simplex Virus Type 2 Infection Among Middle-Age Women in Brazil and the Philippines , 2001, Sexually transmitted diseases.

[45]  T. Dragani,et al.  Libri Ricevuti: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans , 1992 .